Work

Abstract CT250: A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct250

Authors: Omar Saavedra, Fabricio Racca, Valentina Boni, Emiliano Calvo, Brant Delafontaine, Sylvie Rottey, Bernd Dekeyser, Hans Prenen, Maria deMiguel, Valentina Gambardella, Lionel d'Hondt, Vladimir Galvao, Judit W. Johnson, Jonathan P. McNally, Jennifer Lindelien, Alice Drumheller, Jijun Dong, Samuel P. Murphy, Shalabh Singhal, Naimish Pandya, Nuria Kotecki

Institutions: Ghent University Hospital, Antwerp University Hospital, Center for Biomedical Research of La Rioja, Vall d'Hebron Institute of Oncology, Institut Jules Bordet

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154681002

Cites:

Cited by:

Related to: